NEOS Investment Management LLC Has $732,000 Stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

NEOS Investment Management LLC reduced its holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 60.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 17,693 shares of the company’s stock after selling 26,990 shares during the period. NEOS Investment Management LLC’s holdings in Mirum Pharmaceuticals were worth $732,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the business. Congress Wealth Management LLC DE bought a new stake in Mirum Pharmaceuticals during the fourth quarter worth about $414,000. KLP Kapitalforvaltning AS bought a new stake in shares of Mirum Pharmaceuticals during the 4th quarter worth approximately $277,000. Teacher Retirement System of Texas boosted its holdings in shares of Mirum Pharmaceuticals by 19.7% in the 4th quarter. Teacher Retirement System of Texas now owns 10,613 shares of the company’s stock valued at $439,000 after buying an additional 1,748 shares during the last quarter. Swiss National Bank boosted its holdings in shares of Mirum Pharmaceuticals by 1.9% in the 4th quarter. Swiss National Bank now owns 70,300 shares of the company’s stock valued at $2,907,000 after buying an additional 1,300 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Mirum Pharmaceuticals by 162.6% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 176,960 shares of the company’s stock valued at $7,317,000 after buying an additional 109,585 shares in the last quarter.

Insider Buying and Selling

In other news, CEO Christopher Peetz sold 7,489 shares of the company’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total transaction of $320,678.98. Following the completion of the sale, the chief executive officer now directly owns 119,359 shares in the company, valued at approximately $5,110,952.38. This represents a 5.90 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, COO Peter Radovich sold 7,879 shares of the firm’s stock in a transaction on Monday, March 17th. The stock was sold at an average price of $44.21, for a total value of $348,330.59. Following the completion of the transaction, the chief operating officer now owns 18,672 shares in the company, valued at $825,489.12. The trade was a 29.67 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 133,679 shares of company stock valued at $6,007,081 over the last 90 days. 22.87% of the stock is owned by corporate insiders.

Mirum Pharmaceuticals Stock Performance

MIRM opened at $45.99 on Monday. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. The company has a market capitalization of $2.25 billion, a PE ratio of -22.77 and a beta of 1.04. The business has a fifty day simple moving average of $48.01 and a 200 day simple moving average of $43.89. Mirum Pharmaceuticals, Inc. has a 1 year low of $23.14 and a 1 year high of $54.23.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.22). Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The business had revenue of $99.41 million during the quarter, compared to analyst estimates of $96.64 million. Research analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Analyst Upgrades and Downgrades

MIRM has been the subject of a number of recent analyst reports. HC Wainwright increased their price target on shares of Mirum Pharmaceuticals from $66.00 to $72.00 and gave the company a “buy” rating in a research note on Friday, February 28th. Robert W. Baird upped their price objective on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an “outperform” rating in a research note on Thursday, February 27th. Ten investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $58.20.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.